- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01273259
Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults
February 8, 2022 updated by: University Hospital, Bordeaux
Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults. Phase 2 Trial
DHEA prevents and reverses chronic hypoxic pulmonary hypertension in a chronic hypoxic-pulmonary hypertension model in the rat.
However, no study has been performed in human.
The purpose of this study is to determine if DHEA is effective in the treatment of respiratory pulmonary hypertension in adults with Chronic Obstructive Pulmonary Disease (COPD) on exercise capacity and haemodynamic variables.
Patients will receive after randomisation either 25 mg/day or 200mg/day oral DHEA over a one-year period.
Evaluation concerns clinical parameters, echocardiography and right catheterization after and before treatment.
Primary end-point is the six-minute walk test.
This is a prospective double blind, randomised, placebo controlled study which will be realized in four university hospitals in France : Bordeaux, Strasbourg, Toulouse and Limoges.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
51
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bordeaux, France
- University Hospital, Bordeaux
-
Limoges, France
- CHU de Limoges
-
Strasbourg, France
- CHU de Strasbourg
-
Toulouse, France
- CHU de Toulouse
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18 years old and ≤ 75 years old
- Chronic Obstructive Pulmonary Disease with FEVs/VC < 70% (*)
- Respiratory pulmonary hypertension with mean pulmonary arterial pressure ≥ 20 mmHg (*) related to normal pulmonary capillar pressure assessed by catheterization of the right side of the heart (pulmonary capillary wedge pressure ≤12mmHg)
- PO2 ≤ 70 mmHg assessed by arterial gasometry at ease
- If oxygenotherapy then oxygenotherapy more than 6 months before pre-screening
- Written informed consent
(*) Criteria assessed from last health check or the last exams for COPD diagnosis
Exclusion Criteria:
- clinical instability and/or respiratory exacerbation dangerous for catheterization
- Pregnancy (ßHCG > 20 UI /l) or breastfeeding on going
- General corticotherapy > 0,5 mg/kg/day prednisolon equivalent
- Hepatic insufficiency (TP < 50%) or renal insufficiency (creatininemia > 130 µmol/l) or diabetes mellitus type I or II (treated by oral antidiabetic or insulin)
- Left-heart failure (coronary heart disease and/or left valvulopathy)
- High level of prostatic specific antigen (PSA) (> 7ng/ml)
- Cancer antecedent or treatment on going
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 200 mg /day arm
|
DHEA : 200 mg/day hard gelatine capsule
DHEA : 25 mg/day hard gelatine capsule
|
Experimental: 25 mg/day arm
|
DHEA : 200 mg/day hard gelatine capsule
DHEA : 25 mg/day hard gelatine capsule
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy of DHEA on exercise capacity (six-minute walk test)
Time Frame: inclusion and one year of treatment
|
inclusion and one year of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pulmonary vascular resistances
Time Frame: Inclusion and after one year of treatment
|
Inclusion and after one year of treatment
|
Pulmonary and systemic arterial pressures (mean, systolic and diastolic)
Time Frame: Inclusion and after one year of treatment
|
Inclusion and after one year of treatment
|
Safety / Compliance
Time Frame: along one year of treatment
|
along one year of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 6, 2008
Primary Completion (Actual)
June 5, 2015
Study Completion (Actual)
June 5, 2015
Study Registration Dates
First Submitted
January 7, 2011
First Submitted That Met QC Criteria
January 7, 2011
First Posted (Estimate)
January 10, 2011
Study Record Updates
Last Update Posted (Actual)
February 9, 2022
Last Update Submitted That Met QC Criteria
February 8, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2003/04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on DHEA Treatment
-
University Hospital, BordeauxUnknownChronic Obstructive Pulmonary Disease | Hypertension, PulmonaryFrance
-
EndoCeutics Inc.Completed
-
Cairo UniversityCompleted
-
National Institute on Aging (NIA)Completed
-
Shaare Zedek Medical CenterUnknownInfertility, Female | In-Vitro Fertilization
-
The University of Hong KongCompletedFemale Infertility Due to Diminished Ovarian ReserveHong Kong
-
National Center for Complementary and Integrative...Completed
-
Virginia Center for Reproductive MedicineWithdrawn
-
Mayo ClinicNational Institutes of Health (NIH); National Institute on Aging (NIA)Completed
-
Mayo ClinicNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedAging | Dehydroepiandosterone Replacement | DHEA ReplacementUnited States